

Letter to the Editor

Efficacy of systematic catheter locks solution of taurolidine/heparin versus taurolidine/urokinase in end-stage renal insufficiency stage 5D

Eficacia de los sellados sistemáticos de catéter con taurolidina/heparina versus taurolidina/uroquinasa en pacientes con insuficiencia renal crónica estadio 5D

Dear Editor,

Different studies have shown how patients in a haemodialysis programme with native arteriovenous fistulas (nAVF) have a higher patency rate and fewer associated vascular complications.¹ However, even though nAVF are the best type of vascular access, according to the latest data from the Registro de Enfermos Renales de Cataluña (RMRC) [Catalonia Registry of Patients with Kidney Disease],² year on year the rate of use has been reducing (59.8%) and only 39.9% of those who started haemodialysis in 2018 did so with this type of vascular access. Use of the venous catheter as access is therefore an increasing reality related to the older average age of our patients and the coexistence with different cardiopulmonary comorbidity factors (low cardiac output and severe pulmonary hypertension).

The main complications associated with central venous catheters are mechanical dysfunction (fibrin sheath and thrombosis) and endovascular infection. Catheter-related bloodstream infection (CRBSI) is considered the leading cause of hospital admission, at times leading to severe septic complications and requiring removal of the catheter, with the consequent increase in related morbidity and mortality rates.³

Different authors have described that catheters become colonised by microorganisms, which produce a mucopolysaccharide matrix (biofilm) over the surface of the catheter, and this plays a significant role in the development of CRBSI, as it protects the microorganisms from the immune system and different antimicrobial agents.^{4,5}

Currently, advances in the prevention of CRBSI have placed particular emphasis on the use of catheter lock solutions deposited in the lumen of the catheter after each dialysis session aiming to maintain the device patent; this has been shown to be an effective way of preventing infection, possibly by reducing biofilm formation.⁵ Our group concluded based on previous studies that locking the catheter lumen with an antiseptic solution with taurolidine-heparin significantly reduces not only the rate of bacteraemia and the inflammatory response, but also the formation of adherent biological material.^{6,7} Recent studies show the superiority of lock solutions with taurolidine in its different combinations compared to the use of 4% citrate alone (lower rate of CRBSI and dysfunction), particularly with the use of the preparation containing urokinase.^{8,9} However, currently there is little scientific evidence on whether or not there are significant differences between the different formulations containing taurolidine (heparin vs urokinase) and whether the therapeutic change is cost-effective.

The main aim of this research was to analyse whether the systematic lock of the catheter with taurolidine-urokinase (T-U: 4% taurolidine-citrate and 25,000 IU urokinase) during the long interdialytic period produces fewer complications as compared to the conventional regimen of taurolidine-heparin (T-Hep: 4% taurolidine-citrate and 500 IU heparin) in each haemodialysis session.

We conducted an observational, retrospective cohort analysis (2013–2018) in 57 prevalent patients with CKD stage 5D (23 T-Hep and 34 T-U), with a mean age of 66.2 ± 14.5 years (35–93) and 61.4% male. No significant differences were found between subgroups in terms of socio-demographic variables, biochemical parameters or haemodialysis adequacy. During the follow-up period, a total of 25 replacements were per-

Table 1 – Analysis of the economic costs by tunnelled catheter lock subgroup (T-Hep vs T-U).

Unit price	T-Hep (N = 23)	T-U (N = 34)	P value
Lock ^a	€202 ± 5.90 (213–189)	€400.60 ± 13.80 (426–369)	.000*
Urokinase ^b	€2.10 ± 10.10 (48.90–0)	€2.80 ± 11.60 (48.90–0)	.801
Admission for bacteraemia ^c	€150.90 ± 723.90 (3,472–0)	€124 ± 723 (4,216–0)	.799
Replaced due to dysfunction ^d	€1000 ± 1266.30 (3,800–0)	€473.50 ± 1093 (3,800–0)	.033*
Total mean cost ^e	€1355.10 ± 1343.30 (4,003.80–97.50)	€1001 ± 1564.20 (7,926.10–369.20)	.494

^a Cost lock/session: T-Hep €5/vial and T-U €19.80/vial.

^b Cost vial of urokinase (100,000 IU): €248.

^c Cost day of hospital stay on ward due to infection: €248.

^d Catheter replacement due to dysfunction: simple replacement €1400/procedure; and replacement with percutaneous transluminal angioplasty (PTA) over fibrin sheath €1900/procedure.

^e Mean cost/patient adjusted to the time the catheter remained working in each of the study subgroups.

* P < .05.




Fig. 1 – Survival curves (Kaplan-Meier) analysing primary patency (PP) in each of the tunnelled catheter lock subgroups (T-Hep vs T-U).

formed due to dysfunction, 16 in the T-Hep group and nine in the T-U group; $P = .003$. A total of two bacteraemia episodes were identified during the follow-up period, one in each group ($P = NS$).

Fig. 1 shows the different rates of primary patency (PP) in each of the study subgroups. The PP in the group locked with T-U was significantly higher, 1105.9 ± 202.9 days (708.1–1503.6) than that of the T-Hep group, 261.5 ± 53 days (157.5–365.4); $P = .014$. Table 1 shows an analysis of the mean cost-effectiveness during the follow-up period in each of the study subgroups. As can be seen, the average cost was higher in the group with T-U lock, albeit with a lower cost for angiography/radiological procedures due to dysfunction.

In the search for new lock solutions, an American study recently published concluded that systematic locking with sodium bicarbonate significantly reduces the rate of thrombosis (0.17 episodes/1000 catheter days vs 4.1 episodes/1000 catheter days; $P < .0001$) and endovascular bacteraemia (0.17 episodes/1000 catheter days vs 2.6 episodes/1000 catheter days; $P = .0004$) compared to saline.¹⁰ This potential dual beneficial effect of bicarbonate as an antithrombotic and anti-infective agent should therefore be investigated in the future.

According to the results obtained in our study, the use of systematic locking with the combination T-U in the long interdialytic period significantly reduces the number of replacements due to dysfunction, increasing primary patency rates with no additional financial cost. Nevertheless, the present data is preliminary and will need to be correlated with the design of future prospective, randomised studies.

Funding

The authors declare that they have not received funding for this article.

REFERENCES

- Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. *Kidney Int.* 2001;60:1443–51.
- Registre de Malalts Renals de Catalunya. Informe estadístic 2018. OCATT. Generalitat de Catalunya. Departament de Salut [accessed Apr 2020]. Available from: <http://trasplantaments.gencat.cat/web/.content/minisite/trasplantament/registres.activitat/registre.de.malalts.renals/arxiu/Informe-RMRC-2018.pdf>.
- Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. *Am J Kidney Dis.* 2004;44:779–91.
- Krishnasami Z, Carlton D, Bimbo L, Taylor ME, Balkovetz DF, Barker J, et al. Management of hemodialysis catheter-related bacteremia with an adjunctive antibiotic solution. *Kidney Int.* 2002;61:1136–42.
- Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. *Nephrol Dial Transplant.* 2008;23:1666–72.
- Fontseré N, Cardozo C, Donate J, Soriano A, Muros M, Pons M, et al. Lock tunneled catheters with Taurolidine-citrate-heparin lock solution significantly improves inflammatory profile in hemodialysis patients. *Antimicrob Agents Chemother.* 2014;58:4180–4.
- Jiménez Hernández M, Soriano A, Filella X, Calvo M, Coll E, Rebled JM, et al. Impact of locking solutions on conditioning biofilm formation in tunneled haemodialysis catheters and inflammatory response activation. *J Vasc Access.* 2020. <http://dx.doi.org/10.1177/1129729820942040>.
- Winnicki W, Herkner H, Lorenz M, Handisurya A, Kikic Z, Bielez B, et al. Taurolidine-based catheter lock regimen

significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. *Kidney Int.* 2018;75:3-60.

9. Al-Ali F, Hamdy AF, Hamad A, Elsayed M, Iqbal ZZ, Elsayed A, et al. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study. *Nephrol Dial Transplant.* 2018;33:619-26.
10. El-Hennawy AS, Frolova E, Romney WA. Sodium bicarbonate catheter lock solution reduces hemodialysis catheter loss due to catheter-related thrombosis and blood stream infection: an open-label clinical trial. *Nephrol Dial Transplant.* 2019;34:1739-45.

Néstor Fontseré^{a,*}, Alex Soriano^b, Gaspar Mestres^c, Patricia Bermudez^d, Federico Zarco^d, Valentín Lozano^a, Lida Rodas^a, Jose Broseta^a, Marta Arias^a, Francisco Maduell^a

^a Unidad Funcional de Acceso Vascular, Servicio de Nefrología, Hospital Clínico de Barcelona, Barcelona, Spain

^b Unidad Funcional de Acceso Vascular, Servicio de Enfermedades Infecciosas, Hospital Clínico de Barcelona, Barcelona, Spain

^c Unidad Funcional de Acceso Vascular, Servicio de Cirugía Vascular, Hospital Clínico de Barcelona, Barcelona, Spain

^d Unidad Funcional de Acceso Vascular, Servicio de Radiología Vascular Intervencionista, Hospital Clínico de Barcelona, Barcelona, Spain

*Corresponding author.

E-mail address: fontser@clinic.cat (N. Fontseré).

<https://doi.org/10.1016/j.nefro.2021.02.013>

2013-2514/© 2021 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

COVID-19 reinfection in a kidney transplant recipient, time for rethinking?

Reinfección por COVID-19 en un paciente portador de trasplante renal, ¿tiempo para reflexionar?

Dear Editor:

COVID-19 reinfections in immunocompromised patients are a challenge for scientific community. Here we present the first case of a kidney transplant recipient with a lethal COVID-19 reinfection.

He is a 60-year-old male, with chronic kidney disease (CKD) due to focal and segmental glomerulosclerosis that received his first kidney transplant 2004. In treatment with prednisone and rapamycin since 2007 when we was diagnosed of a hepatocellular carcinoma.

In August 2020, after a close contact to a COVID-19 family member, he developed mild symptoms (cough and low-grade fever) and SARS-CoV-2 infection was confirmed by a positive nasopharyngeal real-time reverse transcription-polymerase chain reaction (rRT-PCR) (Fig. 1). The clinical course was favorable, and he did not need further clinical assistance in that moment. A confirmatory rRT-PCR was performed showing a negative result.

In December 2020 and January 2021, he was admitted in the hospital due to two episodes of urinary tract infection caused by *Staphylococcus aureus* and *Serratia marcescens*. In both hospitalizations, rRT-PCR were repeated five times (12th, 30th

December and 4th, 9th, 17th January 2021) resulting negative in all of them. A chest X-ray performed on 12th December 2020 showed very low intensity bilateral infiltrates. In addition, on 8th January 2021, a chest-abdomen computed tomography scan demonstrated bilateral infiltrates in both hemithorax, probably as a residual lesion of the SARS-CoV-2 previous infection (Fig. 2). After diuretic and antibiotic treatment, chest X-ray improved significantly, and the patient was discharge asymptomatic 20th January 2021.

However, 28th January 2021, the patient was again admitted due to respiratory fever and acute injury of the allograft function. A chest X-ray showed bilateral infiltrates with unilateral pleural effusion. A new rRT-PCR confirmed SARS-CoV-2 infection by the same viral genotype, so immunosuppression was stopped, and dexamethasone was started. A thoracentesis of the pleural effusion demonstrated SARS-CoV-2 in the obtained sample. Antibodies (IgM and IgG) for SARS-CoV2 resulted negative. Although he was theoretically immunosuppressed, lymphocyte populations were normal. Despite established treatment including high flux oxygen, the patient deceased on 5th February 2021.

Several doubts have emerged around reinfections in general population. Technical errors in specimen collection or false negative results in rRT-PCR have been demonstrated in many patients driving to mistakes in COVID-19 reinfections. In

DOI of original article:

<https://doi.org/10.1016/j.nefro.2021.02.004>.